Cocrystal Pharma, Inc. (COCP) Bundle
A Brief History of Cocrystal Pharma, Inc. (COCP)
Formation and Early Years
Formation and Early Years
Cocrystal Pharma, Inc. was founded in 2009, focusing primarily on the development of antiviral therapies for various infectious diseases. The company utilizes a novel technology platform that enables the design of co-crystal forms of existing drugs aimed at improving their efficacy and safety profiles.
Public Offering and Financial Overview
In 2017, Cocrystal Pharma became a publicly traded entity, listed on the NASDAQ under the ticker symbol COCP. The company raised approximately $9.8 million through a public offering in September 2017.
As of October 2023, the company reported cash and equivalents amounting to $10.5 million. The total liabilities stood at $18.9 million, reflecting the ongoing investments in research and development.
Key Partnerships and Collaborations
Cocrystal Pharma has established several partnerships over the years:
- In 2015, a significant collaboration was initiated with the National Institutes of Health (NIH) for the development of antiviral therapies.
- In 2020, a partnership with Pfizer for the development of promising antiviral candidates was announced.
Research and Development Focus
The company's primary focus includes:
- Leading antiviral programs targeting hepatitis C, influenza, and coronaviruses.
- Advancing its platform technology for drug development.
As of 2023, Cocrystal has several investigational new drugs (INDs) filed, targeting a broad spectrum of diseases.
Recent Milestones
In March 2023, Cocrystal announced the successful completion of Phase 1 clinical trials for its lead compound targeting COVID-19, which demonstrated favorable safety and pharmacokinetic profiles.
Preliminary results showed a viral load reduction of 70% in treated subjects compared to placebo.
Financial Performance Metrics
As of the end of Q3 2023, Cocrystal Pharma reported the following key financial metrics:
| Financial Metric | Amount (in millions) |
|---|---|
| Revenue | $2.1 |
| Net Loss | $(5.4) |
| Research and Development Expenses | $6.8 |
| General and Administrative Expenses | $3.2 |
| Cash on Hand | $10.5 |
Market Performance
As of October 2023, the stock price of Cocrystal Pharma (COCP) was approximately $1.15, showing a 15% increase year-to-date amidst the positive clinical trial results.
The company's market capitalization is around $60 million based on recent trading activity.
A Who Owns Cocrystal Pharma, Inc. (COCP)
Company Overview
Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for areas of unmet medical need, specifically targeting viral infections such as COVID-19.
Stock Ownership
As of the latest filings, the major institutional shareholders of Cocrystal Pharma, Inc. include:
| Shareholder | Shares Owned | % of Total Shares |
|---|---|---|
| BlackRock, Inc. | 1,089,000 | 9.34% |
| Renaissance Technologies LLC | 873,500 | 7.36% |
| Geode Capital Management, LLC | 860,000 | 7.24% |
| Hudson Bay Capital Management LP | 750,000 | 6.38% |
| Harris Associates L.P. | 650,000 | 5.53% |
Executive Ownership
Key executives and board members also hold significant shares in Cocrystal Pharma:
| Name | Position | Shares Owned | % of Total Shares |
|---|---|---|---|
| Dr. Gary Wilcox | CEO | 500,000 | 4.25% |
| Dr. James O. McCune | CSO | 300,000 | 2.55% |
| Dr. Michael H. P. F. L. Lesch | Board Member | 150,000 | 1.27% |
| Dr. Robert M. H. R. G. Goller | Board Member | 100,000 | 0.85% |
Insider Transactions
Recent insider transactions have included:
- Dr. Gary Wilcox purchased 50,000 shares on January 15, 2023.
- Dr. James O. McCune sold 20,000 shares on February 10, 2023.
- Dr. Michael H. P. F. L. Lesch purchased 30,000 shares on March 5, 2023.
- Dr. Robert M. H. R. G. Goller sold 10,000 shares on March 12, 2023.
Market Capitalization
As of October 2023, the market capitalization of Cocrystal Pharma, Inc. is approximately $39 million, reflecting its position within the biotechnology sector.
Stock Performance
The share price of Cocrystal Pharma, Inc. (COCP) as of October 20, 2023, stands at $1.30, with a year-to-date performance showing a decline of 15%.
Research & Development Investments
Cocrystal Pharma's R&D investment for the fiscal year 2023 was reported at $12 million, underscoring its commitment to developing antiviral therapies.
Funding and Partnerships
In the past year, Cocrystal Pharma has secured approximately $20 million in funding rounds, with prominent partnerships including:
- A collaboration with the National Institutes of Health (NIH) for developing next-generation antiviral drugs.
- Partnership with a major pharmaceutical company for commercialization of its lead candidate.
Employee Count
The company currently employs approximately 40 individuals across various roles in research, development, and administration.
Conclusion
Cocrystal Pharma, Inc. has established a well-defined ownership structure with institutional investors playing a significant role. The financial outlook and investment in R&D align with its strategic focus on antiviral drug development.
Cocrystal Pharma, Inc. (COCP) Mission Statement
Company Overview
Cocrystal Pharma, Inc. is a biotechnology company focused on developing antiviral therapeutics. The company aims to address unmet medical needs by creating innovative therapies for viral infections.
Mission Statement
The mission of Cocrystal Pharma, Inc. is to discover, develop, and deliver innovative antiviral therapies to improve patient outcomes and quality of life, leveraging advanced drug development technologies.
Core Values
- Innovation
- Integrity
- Collaboration
- Commitment to Patients
Recent Financial Performance
As of the end of Q2 2023, Cocrystal Pharma reported the following financial data:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $1.2 million |
| Net Loss | ($3.5 million) |
| Research & Development Expenses | $2.2 million |
| Cash and Cash Equivalents | $10.1 million |
Recent Developments
In 2023, Cocrystal Pharma announced significant progress in its clinical trials, particularly in the field of influenza and hepatitis C therapies. The company has focused its resources on:
- Advancing the clinical pipeline for antiviral candidates
- Building strategic partnerships
- Enhancing research capabilities
Research Focus
The company primarily focuses on developing therapies for:
- Influenza
- Hepatitis C
- Coronavirus
Clinical Pipeline
| Drug Candidate | Target Indication | Phase |
|---|---|---|
| CC-31244 | Hepatitis C | Phase 2 |
| CC-42344 | Influenza | Phase 1 |
| CC-45244 | COVID-19 | Preclinical |
Market Position
Cocrystal Pharma operates within a competitive biotechnology landscape. The current market focuses on:
- Antiviral drug development
- Increasing demand for effective treatments
- Regulatory advancements for drug approvals
Vision for the Future
Cocrystal Pharma envisions becoming a leader in antiviral drug discovery, targeting global health challenges through innovation and partnership.
How Cocrystal Pharma, Inc. (COCP) Works
Company Overview
Company Overview
Cocrystal Pharma, Inc. (COCP) is a biotechnology company focused on developing antiviral therapeutics. The company utilizes its proprietary technology platform to design and develop novel therapeutics targeting infectious diseases. As of October 2023, Cocrystal’s market capitalization stands at approximately $66.1 million.
Business Model
Cocrystal operates primarily in the pharmaceutical sector, engaging in research, development, and commercialization of therapeutics. The business model is focused on:
- Research and development (R&D) of antiviral drugs.
- Partnerships and collaborations with larger pharmaceutical companies.
- Licensing agreements for its drug candidates.
Financial Performance
Cocrystal Pharma has reported the following financial figures for FY 2022:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $2.5 million |
| Net Loss | ($9.7 million) |
| Research & Development Expenses | $7.2 million |
| General & Administrative Expenses | $2.5 million |
| Cash & Cash Equivalents | $15.3 million |
Research and Development Pipeline
Cocrystal’s R&D pipeline includes several antiviral candidates with the following details:
| Drug Candidate | Indication | Development Stage |
|---|---|---|
| CC-31244 | HCV (Hepatitis C Virus) | Phase 2 |
| CC-31350 | Influenza Virus | Phase 1 |
| CC-93269 | COVID-19 | Preclinical |
Collaborations and Partnerships
Cocrystal has engaged in multiple collaborations to advance its drug development:
- In 2022, Cocrystal entered a collaboration agreement with Merck & Co. for the development of HCV treatments.
- In 2023, the company announced a partnership with Chimerix to co-develop antiviral drugs.
Funding and Investments
Recent funding rounds have shown significant investment in Cocrystal:
| Funding Round | Date | Amount Raised (USD) |
|---|---|---|
| Public Offering | July 2023 | $10 million |
| Private Placement | January 2023 | $5 million |
| Grant Funding | March 2022 | $2 million |
Market Position and Competitors
In the antiviral therapeutics market, Cocrystal faces competition from:
- Gilead Sciences - Known for its HCV treatments.
- Bristol-Myers Squibb - Strong in HIV and infectious disease space.
- AbbVie - Another key player in antiviral drug development.
Future Outlook
As of October 2023, analysts project that Cocrystal Pharma could achieve significant growth depending on the success of its clinical trials and partnerships.
How Cocrystal Pharma, Inc. (COCP) Makes Money
Revenue Streams
Cocrystal Pharma, Inc. generates revenue primarily through collaborations, licensing agreements, and its own product development within the biotechnology sector. The company focuses on developing antiviral therapeutics, particularly for treating diseases caused by RNA viruses.
Collaborative Agreements
Cocrystal has entered into several collaborative agreements with pharmaceutical companies, which provide funding and resources for the development of its drug candidates. For instance, Cocrystal has a collaboration with Merck to develop antiviral therapies. This agreement includes milestone payments and potential royalties that significantly contribute to revenue.
Licensing Agreements and Royalties
Licensing agreements that allow other companies to utilize Cocrystal’s technology or drug candidates also form an essential component of its revenue model. In 2022, Cocrystal received approximately $3 million in licensing fees from partners.
Product Development and Sales
The company focuses on developing drug candidates like CC-312 and CC-42344, aimed at treating various viral infections. As of October 2023, Cocrystal has not yet generated significant product sales but expects to launch its first products in upcoming years, promising potential future revenue.
Financial Performance
As of the fiscal year 2023, Cocrystal Pharma reported total revenues of approximately $4 million, up from $1 million in 2022, primarily driven by collaborative and licensing agreements. The company’s expenses for research and development were around $7 million, reflecting heavy investment in drug development.
Funding and Investment
Cocrystal Pharma has raised capital through various financing rounds, including public and private offerings. In a recent equity financing round in 2023, the company raised $10 million, which will support ongoing clinical trials and research initiatives.
Recent Financial Highlights
| Financial Metric | 2023 | 2022 |
|---|---|---|
| Total Revenue | $4 million | $1 million |
| R&D Expenses | $7 million | $5 million |
| Licensing Revenue | $3 million | $500,000 |
| Net Loss | $(5 million) | $(4 million) |
| Cash and Equivalents | $12 million | $8 million |
Market Potential and Future Outlook
The antiviral drug market is projected to expand significantly, and Cocrystal positions itself to capitalize on this growth. According to industry reports, the global antiviral therapeutics market was valued at approximately $30 billion in 2022 and is expected to reach $50 billion by 2027.
Strategic Partnerships
Strategic partnerships enhance Cocrystal's capabilities and market reach. In 2023, collaborations with leading pharmaceutical companies provided critical expertise and resources. The collaboration with Merck is a prime example, focusing on developing therapies for COVID-19 and other viral diseases.
Investment in R&D
Cocrystal Pharma’s investment in research and development is crucial for its long-term success. The company allocated 70% of its total budget to R&D in 2023, further emphasizing its commitment to innovative drug discovery.
Cocrystal Pharma, Inc. (COCP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support